GLP-1 receptor agonists for Alzheimer’s disease: Lessons from trials and translational challenges
Alzheimer’s disease (AD) is a multifactorial disorder that requires combined therapeutic strategies beyond amyloid clearance. Although GLP-1 receptor agonists show strong mechanistic rationale and supportive epidemiological signals for neuroprotection, large randomized trials in symptomatic AD have yielded negative cli...